TickerFacts.

Immucell Corp (ICCC): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$2.78M
Year ended 2025-12-31
$2.42M
Trailing 12 months to 2026-06-30
2024-12-31: $2.73M2025-12-31: $2.78M$2.78M
2024-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$2.78M+2.0%2026-03-30, From 2025-01-01
2024-12-31$2.73Mn/a2026-03-30, From 2024-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Immucell Corp (ICCC)2025-12-31$2.78M+2.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$6.34M-3.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$9.77M-5.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$112.0K+21.7%
Biomerica Inc (BMRA)2026-05-31$77.0K-11.5%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.19M+48.4%
Volitionrx Ltd (VNRX)2025-12-31$983.7K-11.6%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$3.38M+6.4%
Myriad Genetics Inc (MYGN)2025-12-31$53.70M-12.3%

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗